Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
T-cell dysfunction is a hallmark of B-cell Chronic Lymphocytic Leukemia (CLL), where CLL cells downregulate T-cell responses through regulatory molecules including programmed death ligand-1 (PD-L1) and Interleukin-10 (IL-10). Immune checkpoint blockade (ICB) aims to restore T-cell function by preventing the ligation of inhibitory receptors like PD-1. However, most CLL patients do not respond well to this therapy. Thus, we investigated whether IL-10 suppression could enhance antitumor T-cell activity and responses to ICB. Since CLL IL-10 expression depends on Sp1, we utilized a novel, better tolerated analogue of the Sp1 inhibitor mithramycin (MTM
Document Type
Accepted Manuscript
Publication Date
11-1-2021
Repository Citation
Rivas, J R; Liu, Y; Alhakeem, S S; Eckenrode, J M; Marti, F; Collard, J P; Zhang, Y; Shaaban, K A; Muthusamy, N; Hildebrandt, G C; Chen, L; Thorson, J S; Leggas, M; and Bondada, Subbarao, "Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia." (2021). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 154.
https://uknowledge.uky.edu/microbio_facpub/154
